Skip to content
TrialMatch
Sign up
Recruiting Phase 2

Efficacy and Safety Study of Romiplostim N01 for Cancer Treatment-induced Thrombocytopenia (CTIT) in the Treatment of Leukemia

Create a profile to match View the full record on ClinicalTrials.gov

About this study

Evaluation of the Efficacy and Safety of Romiplostim N01 for the Treatment of Cancer Treatment-Induced Thrombocytopenia (CTIT) in Patients with Leukemia

Condition
Cancer Treatment-induced Thrombocytopenia (CTIT)
Tested
Romiplostim N01
Sponsor
Anhui Provincial Hospital

Who can join

Age
18 to 75 years
Sex
All sexes
Healthy volunteers
Not accepted

Inclusion 10

  • Minimum age: 18 years
  • Maximum age: 75 years
  • Study condition: Cancer Treatment-induced Thrombocytopenia (CTIT)
  • Age between 18 and 75 years, inclusive, regardless of sex;
  • Histologically or pathologically confirmed diagnosis of leukemia;
  • Patients with cancer treatment-induced thrombocytopenia (CTIT) in patients with leukemia due to antitumor therapy, with platelet count \< 50×10⁹/L;
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2;
  • Subjects of childbearing potential agree to use reliable methods of contraception throughout the study period (including male or female condoms, contraceptive foam, gel, film, cream, suppository, abstinence, or intrauterine device);
  • Patients considered by the investigator to potentially benefit from the study treatment;
  • Voluntarily agrees to participate in the clinical trial, is fully informed of the study procedures, and has signed the written informed consent form.

Exclusion 14

  • Pregnant or breastfeeding women;
  • Known hypersensitivity to Romiplostim N01;
  • Presence of hematologic disorders other than cancer treatment-induced thrombocytopenia (CTIT) caused by leukemia treatment, including but not limited to primary immune thrombocytopenia, myeloproliferative disorders, multiple myeloma, or myelodysplastic syndromes;
  • History of thrombocytopenia due to causes other than CTIT within 6 months prior to screening, including but not limited to chronic liver disease, hypersplenism, infections, or bleeding disorders;
  • History of severe thrombotic events or known risk factors for thrombosis, or active thromboembolism requiring anticoagulation therapy;
  • Severe bleeding within 2 weeks prior to screening (requiring more than 2 units of red blood cell transfusion or a sudden ≥10% drop in hematocrit);
  • Use of thrombopoietin receptor agonists (e.g., eltrombopag), recombinant human thrombopoietin (rhTPO), or interleukin-11 (IL-11) within 1 month prior to screening;
  • HIV infection;
  • Chronic active hepatitis B or hepatitis C infection;
  • Presence of severe infection or serious comorbidities involving the heart, liver, lungs, kidneys, nervous system, or metabolic diseases;
  • Participation in any investigational drug or device clinical trial within 28 days prior to baseline visit;
  • Subjects with cognitive impairment or uncontrolled psychiatric disorders;
  • Refusal of the subject and/or legal representative to receive Romiplostim N01 treatment;
  • Deemed unsuitable for enrollment by the investigator (e.g., comorbid conditions that may compromise subject safety or anticipated treatment non-adherence due to financial or other constraints).

Where

1 site, 1 recruiting

The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital)

Hefei, Anhui, China

Recruiting

Contact

Potential match only. Final eligibility is determined by the study team.